{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-097152","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.916017+00:00","generated_at":"2026-05-31T06:15:30.243202+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones","bullets":["Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.","One-time $15M fee paid upfront; Voyager eligible for $130M in development/regulatory/commercial milestones.","Additional sales milestones up to $175M per product plus tiered mid- to high-single-digit royalties.","Novartis' prior option rights for other targets expired as of September 3, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-097152","json":"https://secwatch.observer/filing/0001104659-24-097152.json","markdown":"https://secwatch.observer/filing/0001104659-24-097152.md","text":"https://secwatch.observer/filing/0001104659-24-097152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924097152/0001104659-24-097152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924097152/tm2423222d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:15:30.243202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}